Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1/2 1Phase 1 1

Status

Completed 3Terminated 2

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Lymphoid 5Other hematologic neoplasm 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 23Burkitt Lymphoma 20Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 7Lymphoma, B-Cell 7Lymphoma 5Lymphoma, Large B-Cell, Diffuse 4Leukemia 4Recurrence 3Lymphoma, Non-Hodgkin 2Leukemia, Biphenotypic, Acute 2Philadelphia Chromosome 1Neoplasm, Residual 1Lymphoma, Follicular 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Hematologic Neoplasms 1Blast Crisis 1

Interventions

Cyclophosphamide 444Rituximab 401Etoposide 224Vincristine 215Doxorubicin 201Filgrastim 200Prednisone 176Cytarabine 159Radiotherapy 152fludarabine phosphate 147Methotrexate 137Peripheral Blood Stem Cell Transplantation 129Melphalan 127fludarabine 115Busulfan 99Dexamethasone 93Tacrolimus 75Carmustine 74Granulocyte Colony-Stimulating Factor 73Mycophenolic Acid 71Gemcitabine 66Bortezomib 65Antilymphocyte Serum 65Whole-Body Irradiation 62Cyclosporine 62Bendamustine Hydrochloride 62Lenalidomide 60Ifosfamide 58sargramostim 51Methylprednisolone 49

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × Lymphoma × Inotuzumab Ozogamicin × Clear all
NCT03856216 2026-04-15

Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation

M.D. Anderson Cancer Center

Phase 2 Terminated
15 enrolled 11 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01232556 2019-01-08

A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy

Pfizer

Phase 3 Terminated
338 enrolled 15 charts
Lymphoid

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT00073749 2018-12-17

Study Evaluating CMC-544 In B-Cell Non-Hodgkin's Lymphoma

Pfizer

Phase 1 Completed
79 enrolled 24 charts
Lymphoid

Lymphoma, Lymphoma, B-Cell

NCT00299494 2018-03-08

Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL)

Pfizer

Phase 1/2 Completed
119 enrolled 60 charts
Lymphoid

Lymphoma, Lymphoma, B-Cell

NCT00868608 2017-10-31

Study Evaluating Inotuzumab Ozogamicin (CMC-544) In Indolent Non-Hodgkins Lymphoma

Pfizer

Phase 2 Completed
81 enrolled 24 charts
Lymphoid

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡